Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
Open accessAbstract
There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however this has never been tested in humans. Following a double-blind, placebo-controlled, parallel group design, we utilized an ultra-high field multimodal brain imaging approach and demonstrated that psilocybin (0.17 mg/kg) induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution). Whereas higher levels of medial prefrontal cortical glutamate were associated with negatively experienced ego dissolution, lower levels in hippocampal glutamate were associated with positively experienced ego dissolution. Such findings provide further insights into the underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state. Importantly, they may also provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In ego dissolution states, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes.
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [42]
The Discussion reports that the degree of ego dissolution has been found to correlate with long-term clinical outcomes and increased well-being. It does not say that ego dissolution helps individuals engage with beliefs or emotions through detachment or decentration, so the proposed pathway to therapeutic outcomes is unsupported. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThe potential of classic psychedelics to alter glutamate in the human cortex, albeit in a region-dependent manner, has been demonstrated.
“The potential of classic psychedelics to alter glutamate in the human cortex, albeit in a region-dependent manner, has been demonstrated (92).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190 · see citing works
Correspondence of the brain's functional architecture during activation and rest
Smith, S. M., Fox, P. T., Miller, K. L., Glahn, D. C., Fox, P. M., Mackay, C. E., Filippini, N., Watkins, K. E., Toro, R., Laird, A. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905267106 · Cited by 5,150 · see citing works
<i>Conn</i> : A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks
Whitfield-Gabrieli, S., & Nieto-Castanon, A. (2012) · Brain Connectivity · doi:10.1089/brain.2012.0073 · Cited by 4,885 · see citing works
A method for making group inferences from functional MRI data using independent component analysis
Calhoun, V. D., Adali, T., Pearlson, G. D., & Pekar, J. J. (2001) · Human Brain Mapping · doi:10.1002/hbm.1048 · Cited by 2,994 · see citing works
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2× · see citing works
“A paradoxical effect of serotonergic psychedelics is that acutely they have been found to increase feelings of anxiety [6, 78], whereas clinical trials with psychedelic drugs suggest long-term anxiety relief in patients [11, 12, 14].”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Self-citationBunney, W. E., Hippius, H., Laakmann, G., & Schmauß, M. (1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523 · see citing works
A Baseline for the Multivariate Comparison of Resting-State Networks
Allen, E. A., Erhardt, E. B., Damaraju, E., Gruner, W. E., Segall, J. M., Silva, R. F., Havlíček, M., Rachakonda, S., Fries, J. F., Kalyanam, R., et al. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00002 · Cited by 1,286 · see citing works
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · see citing works
Self-citationNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · see citing works
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · see citing works
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · see citing works
Self-citationRaincloud plots: a multi-platform tool for robust data visualization
Allen, M., Poggiali, D., Whitaker, K. J., Marshall, T. R., & Kievit, R. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15191.1 · Cited by 1,125 · see citing works
The brain's default network and its adaptive role in internal mentation
Andrews-Hanna, J. R. (2012) · The Neuroscientist · doi:10.1177/1073858411403316 · Cited by 1,114 · see citing works
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works
The effect of scan length on the reliability of resting-state fMRI connectivity estimates
Birn, R. M., Molloy, E. K., Patriat, R., Parker, T., Meier, T. B., Kirk, G. R., Nair, V. A., Meyerand, M. E., & Prabhakaran, V. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.099 · Cited by 875 · see citing works
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · see citing works
Self-citationPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · see citing works
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808 · see citing works
Sherry, A. R., & Henson, R. K. (2005) · Journal of Personality Assessment · doi:10.1207/s15327752jpa8401_09 · Cited by 768 · see citing works
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · see citing works
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · see citing works
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · see citing works
Frahm, J., Bruhn, H., Gyngell, M. L., Merboldt, K. D., Hänicke, W., & Sauter, R. (1989) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910090110 · Cited by 711 · see citing works
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · see citing works
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696 · see citing works
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · see citing works
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635 · see citing works
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577 · see citing works
The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas
Carhart-Harris, R. L., & Friston, K. J. (2010) · Brain · doi:10.1093/brain/awq010 · Cited by 574 · see citing works
Mapping the self in the brain's default mode network
Davey, C. G., Pujol, J., & Harrison, B. J. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.022 · Cited by 559 · see citing works
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 1× · see citing works
“Of note, compared to previous psychedelic studies, the dose administered was low to moderate [96], and thus not high enough to induce total ego dissolution.”
ResultAghajanian, G. K., & Marek, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 516 · see citing works
Increased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · see citing works
Self-citationVaidya, V. A., Marek, G. J., Aghajanian, G. K., & Duman, R. S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02785.1997 · Cited by 479 · see citing works
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · see citing works
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470 · see citing works
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · see citing works
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454 · see citing works
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · see citing works
Serotonin and Prefrontal Cortex Function: Neurons, Networks, and Circuits
Puig, M. V., & Gulledge, A. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8214-0 · Cited by 421 · see citing works
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112464827 · Cited by 402 · see citing works
In vivo magnetic resonance spectroscopy of GABA: A methodological review
Puts, N. A. J., & Edden, R. A. E. (2011) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2011.06.001 · Cited by 394 · see citing works
Psychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390 · see citing works
Aghajanian, G. K., & Marek, G. J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01224-x · Cited by 376 · see citing works
The effect of model order selection in group PICA
Abou‐Elseoud, A., Starck, T., Remes, J. J., Nikkinen, J., Tervonen, O. A., & Kiviniemi, V. J. (2010) · Human Brain Mapping · doi:10.1002/hbm.20929 · Cited by 362 · see citing works
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353 · see citing works
Near, J., Harris, A. D., Juchem, C., Kreis, R., Marjańska, M., Öz, G., Slotboom, J., Wilson, M., & Gasparovic, C. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4257 · Cited by 346 · see citing works
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339 · see citing works
Self-citationNeuroplasticity and cellular resilience in mood disorders
Manji, H. K., Moore, G. J., Rajkowska, G., & Chen, G. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000811 · Cited by 339 · see citing works
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · see citing works
Self-citationRoseman, L., Leech, R., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00204 · Cited by 274 · see citing works
Self-citationTHE LEFT MEDIAL TEMPORAL REGION AND SCHIZOPHRENIA: A PET STUDY
Friston, K. J., Liddle, P. F., Frith, C., Hirsch, S. R., & Frackowiak, R. S. J. (1992) · Brain · doi:10.1093/brain/115.2.367 · Cited by 259 · see citing works
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256 · see citing works
Self-citationSmigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · see citing works
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241 · see citing works
Activation of Serotonin Receptors Modulates Synaptic Transmission in Rat Cerebral Cortex
Zhou, F.-M., & Hablitz, J. J. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.6.2989 · Cited by 238 · see citing works
The Role of Glutamate in Anxiety and Related Disorders
Cortese, B. M., & Phan, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010427 · Cited by 231 · see citing works
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · see citing works
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · see citing works
Puig, M. V. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.8.870 · Cited by 223 · see citing works
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219 · see citing works
Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., & Carhart-Harris, R. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-17546-0 · Cited by 214 · see citing works
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212 · see citing works
Self-citationDynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin
Lord, L.-D., Expert, P., Atasoy, S., Roseman, L., Rapuano, K. M., Lambiotte, R., Nutt, D., Deco, G., Carhart-Harris, R. L., Kringelbach, M. L., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.05.060 · Cited by 210 · see citing works
Weber (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00036 · Cited by 205 · see citing works
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197 · see citing works
Self-citationDifferential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
McKenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 195 · see citing works
Hippocampal GABA enables inhibitory control over unwanted thoughts
Schmitz, T. W., Correia, M., Ferreira, C. S., Prescot, A. P., & Anderson, M. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00956-z · Cited by 192 · see citing works
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188 · see citing works
Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 183 · see citing works
Altered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174 · see citing works
Self-citationSub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172 · see citing works
Self-citationSerotonergic regulation of neuronal excitability in the prefrontal cortex
Andrade, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.015 · Cited by 167 · see citing works
Scruggs, J. L., Patel, S., Bubser, M., & Deutch, A. Y. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08846.2000 · Cited by 154 · see citing works
Oldehinkel, M., Mennes, M., Marquand, A. F., Charman, T., Tillmann, J., Ecker, C., Dell’Acqua, F., Brandeis, D., Banaschewski, T., Baumeister, S., et al. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.11.010 · Cited by 148 · see citing works
The Central 5‐HT1A Receptors: Pharmacological, Biochemical, Functional, and Regulatory Propertiesa
Hamon, M., GOZLAN, H., Mestikawy, S. E., Emerit, M. B., Bolaños, F. J., & Schechter, L. E. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16877.x · Cited by 144 · see citing works
Open-Label Trial of Riluzole in Generalized Anxiety Disorder
Mathew, S. J., Amiel, J. M., Coplan, J. D., Fitterling, H. A., Sackeïm, H. A., & Gorman, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2379 · Cited by 134 · see citing works
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 1× · see citing works
“Conversely, it has also been established that, along with the 5-HT2A receptor, psilocin also has a high affinity for the 5-HT1A receptor [70, 71].”
BackgroundScruggs, J. L., Schmidt, D. E., & Deutch, A. Y. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00547-0 · Cited by 126 · see citing works
Çavuş, I., & Duman, R. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00236-1 · Cited by 124 · see citing works
Sipes, T. E., & Geyer, M. A. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199512000-00010 · Cited by 117 · see citing works
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102 · see citing works
The Spectrum of Organic Depersonalization
Lambert, M. V., Sierra, M., Phillips, M. L., & David, A. S. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.141 · Cited by 100 · see citing works
5HT-2 mediation of acute behavioral effects of hallucinogens in rats
Wing, L. L., Tapson, G. S., & Geyer, M. A. (1990) · Psychopharmacology · doi:10.1007/bf02244617 · Cited by 97 · see citing works
Marek, G. J., & Aghajanian, G. K. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00036-5 · Cited by 96 · see citing works
Marek, G. J., & Aghajanian, G. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00043-8 · Cited by 89 · see citing works
Correction of geometric distortion in fMRI data
Jezzard, P. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.010 · Cited by 87 · see citing works
Psychedelics and the science of self-experience
Nour, M. M., & Carhart-Harris, R. L. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.194738 · Cited by 87 · see citing works
Serotonin Induces EPSCs Preferentially in Layer V Pyramidal Neurons of the Frontal Cortex in the Rat
Lambe, E. K. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.974 · Cited by 86 · see citing works
Buckholtz, N. S., Zhou, D.-F., Freedman, D. X., & Potter, W. Z. (1990) · PubMed · Cited by 80 · see citing works
Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors
Gewirtz, J. C., Chen, A. C. H., Terwilliger, R. Z., Duman, R. C., & Marek, G. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00844-4 · Cited by 74 · see citing works
Bombardi, C., & Giovanni, G. D. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3512-6 · Cited by 73 · see citing works
Shungu, D. C., Mao, X., Gonzales, R., Soones, T. N., Dyke, J. P., van der Veen, J. W. C., & Kegeles, L. S. (2016) · NMR in Biomedicine · doi:10.1002/nbm.3539 · Cited by 70 · see citing works
Lemche, E., Surguladze, S. A., Brammer, M. J., Phillips, M. L., Sierra, M., David, A. S., Williams, S., & Giampietro, V. (2013) · CNS Spectrums · doi:10.1017/s1092852913000588 · Cited by 41 · see citing works
Gap junction channels as potential targets for the treatment of major depressive disorder
Ren, Q., Wang, Z., Chu, S., Xia, C., & Chen, N. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4782-7 · Cited by 41 · see citing works
Editorial: the psychopharmacology of extinction—from theory to therapy
Milton, A. L., & Holmes, A. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5152-9 · Cited by 14 · see citing works
The parahippocampal gyrus as a multimodal association area in psychosis
Acioly, M. A., Carvalho, C. H., Tatagiba, M. S., & Gharabaghi, A. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.052 · Cited by 13 · see citing works
Broca's region subserves imagery of motion: A combined cytoarchitectonic and fMRI study
Binkofski, F., Amunts, K., Stephan, K. M., Posse, S., Schormann, T., Freund, H.-J., Zilles, K., & Seitz, R. J. (2000) · Human Brain Mapping · doi:10.1002/1097-0193(200012)11:4
Flagged first, then by citations
Cited by
Sorted by citations
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313 · see citing works
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276 · see citing works
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 290 · see citing works
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269 · see citing works
Self-citationDefault Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256 · see citing works
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221 · see citing works
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2021) · Brain · doi:10.1093/brain/awab406 · Cited by 198 · see citing works
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150 · see citing works
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Línnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 145 · see citing works
Spontaneous and deliberate creative cognition during and after psilocybin exposure
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Rios, B. D., Toennes, S. W., Stiers, P. L. J., Feilding, A., & Ramaekers, J. G. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01335-5 · Cited by 129 · see citing works
Self-citationMolecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127 · see citing works
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 111 · see citing works
Self-citationClassic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 112 · see citing works
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 108 · see citing works
Self-citationWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 106 · see citing works
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99 · see citing works
Canalization and plasticity in psychopathology
Carhart-Harris, R. L., Chandaria, S., Erritzøe, D., Gazzaley, A. H., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D. J., Rosas, F. E., Roseman, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109398 · Cited by 103 · see citing works
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 100 · see citing works
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86 · see citing works
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 89 · see citing works
Self-citationPsychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82 · see citing works
“Inaddition to peripheral measurement of BDNF, another read-out of the effect of psychedelic compound binding of the 5-HT 2A R in human brain, is glutamate release, which unlike BDNF measurements, can be readily quantified in human brain (Dos Santos and Hallak, 2020; Mason et al., 2020).”
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 89 · see citing works
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84 · see citing works
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83 · see citing works
Garland, E. L. (2021) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2021.03.019 · Cited by 78 · see citing works
A complex systems perspective on psychedelic brain action
Girn, M., Rosas, F. E., Daws, R. E., Gallen, C. L., Gazzaley, A. H., & Carhart-Harris, R. L. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.01.003 · Cited by 72 · see citing works
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74 · see citing works
Self-citationAn Integrated theory of false insights and beliefs under psychedelics
McGovern, H. T., Grimmer, H. J., Doss, M. K., Hutchinson, B. T., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. (2024) · Communications Psychology · doi:10.1038/s44271-024-00120-6 · Cited by 74 · see citing works
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69 · see citing works
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 68 · see citing works
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62 · see citing works
Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M. K., Garcia‐Romeu, A., Nayak, S. M., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab026 · Cited by 63 · see citing works
Smausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 60 · see citing works
Sustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 60 · see citing works
Cardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 60 · see citing works
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 58 · see citing works
Burt, J. B., Preller, K. H., Demirtaş, M., Ji, J. L., Krystal, J. H., Vollenweider, F. X., Anticevic, A., & Murray, J. D. (2021) · eLife · doi:10.7554/elife.69320 · Cited by 48 · see citing works
Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T. E., Griffiths, R. R., & Barrett, F. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-73216-8 · Cited by 52 · see citing works
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Glowacki, D. R., Williams, R. R., Wonnacott, M., Maynard, O., Freire, R., Pike, J. E., & Chatziapostolou, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12637-z · Cited by 56 · see citing works
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 49 · see citing works
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P. R., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 48 · see citing works
Hudak, J., Hanley, A. W., Marchand, W. R., Nakamura, Y., Yabko, B. A., & Garland, E. L. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00831-4 · Cited by 47 · see citing works
Prefrontal contributions to the stability and variability of thought and conscious experience
Zamani, A., Carhart-Harris, R. L., & Kalina Christoff, A. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01147-7 · Cited by 45 · see citing works
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 49 · see citing works
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43 · see citing works
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decen-tration, potentially leading to therapeutic outcomes [42, 43].”
BackgroundOnofrj, M., Russo, M., Delli Pizzi, S., De Gregorio, D., Inserra, A., Gobbi, G., & Sensi, S. L. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02691-0 · Cited by 43 · see citing works
Passie, T., Adams, H.-A., Logemann, F., Brandt, S. D., Wiese, B., & Karst, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.005 · Cited by 43 · see citing works
Olsen, A. S., Lykkebo-Valløe, A., Ozenne, B., Madsen, M. K., Stenbæk, D. S., Armand, S., Mørup, M., Ganz, M., Knudsen, G. M., & Fisher, P. M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119716 · Cited by 41 · see citing works
Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 40 · see citing works
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Bedford, P., Hauke, D. J., Wang, Z., Röth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01574-8 · Cited by 40 · see citing works
Self-citationPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 46 · see citing works
IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapy
Mash, D. C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106620 · Cited by 38 · see citing works
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37 · see citing works
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 38 · see citing works
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 36 · see citing works
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 31 · see citing works
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G. K., Ching, T. H. W., Belser, A., & Pittenger, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12135 · Cited by 34 · see citing works
Psilocybin-Assisted Compassion Focused Therapy for Depression
Pots, W. T. M., & Chakhssi, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.812930 · Cited by 33 · see citing works
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 34 · see citing works
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 31 · see citing works
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 31 · see citing works
Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D. (2023) · Psychological Review · doi:10.1037/rev0000455 · Cited by 33 · see citing works
Beating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 28 · see citing works
Roscoe, J., & Lozy, O. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085222 · Cited by 29 · see citing works
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 25 · see citing works
Floris, G., Dabrowski, K. R., Zanda, M. T., & Daws, S. E. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02788-y · Cited by 30 · see citing works
Buchborn, T., Kettner, H., Kärtner, L., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1232459 · Cited by 29 · see citing works
Rapid-acting antidepressant drugs modulate affective bias in rats
Hinchcliffe, J. K., Stuart, S. A., Wood, C. M., Bartlett, J. M., Kamenish, K., Arban, R., Thomas, C. W., Selimbeyoglu, A., Hurley, S., Hengerer, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2403 · Cited by 27 · see citing works
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 27 · see citing works
Mortaheb, S., Fort, L. D., Mason, N. L., Mallaroni, P., Ramaekers, J. G., & Athena Demertzi, A. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.04.001 · Cited by 25 · see citing works
Self-citationSzpręgiel, I., & Bysiek, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00660-y · Cited by 26 · see citing works
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 24 · see citing works
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24 · see citing works
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023) · Network Neuroscience · doi:10.1162/netn_a_00349 · Cited by 22 · see citing works
Self-citationAn international mega-analysis of psychedelic drug effects on brain circuit function
Girn, M., Doss, M. K., Roseman, L., Preller, K. H., Palhano-Fontes, F., Pasquini, L., Barrett, F. S., Mallaroni, P., Mason, N. L., Timmermann, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04287-9 · Cited by 23 · see citing works
Self-citationDworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22 · see citing works
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 22 · see citing works
Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power
Meikle, S. E., Carter, O. L., & Bedi, G. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231200164 · Cited by 22 · see citing works
Inter-individual variability in neural response to low doses of LSD
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L., Theunissen, E. L., Liechti, M. E., Duthaler, U., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03013-8 · Cited by 21 · see citing works
Self-citationOtto, M. E., van der Heijden, K. V., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., Jacobs, G. E., & van Hasselt, J. G. C. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01454-4 · Cited by 21 · see citing works
Brito, M. A., Li, D., Fields, C. W., Rybicki-Kler, C., Dean, J. G., Liu, T., Mashour, G. A., & Pal, D. (2021) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005835 · Cited by 20 · see citing works
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21 · see citing works
The Health and Clinical Benefits of Medicinal Fungi
Hobbs, C. (2023) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2023_230 · Cited by 21 · see citing works
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 19 · see citing works
A novel ego dissolution scale: A construct validation study
Sleight, F. G., Lynn, S. J., Mattson, R. E., & McDonald, C. W. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103474 · Cited by 20 · see citing works
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 20 · see citing works
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 21 · see citing works
Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation
Moujaes, F., Rieser, N. M., Phillips, C. L. M., de Matos, N. M. P., Brügger, M., Duerler, P., Smigielski, L., Stämpfli, P., Seifritz, E., Vollenweider, F. X., et al. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.07.003 · Cited by 20 · see citing works
Psychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 16 · see citing works
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 20 · see citing works
Molecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 21 · see citing works
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19 · see citing works
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20 · see citing works
“Many consider it to be a typical effect of both LSD and psilocybin (Mason et al., 2020; Tagliazucchi et al., 2016), particularly at higher doses (Holze et al., 2021).”
BackgroundBarrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 18 · see citing works
Wang, S., Kim, S., Choi, W.-S., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1134 · Cited by 18 · see citing works
Computational models of the “active self” and its disturbances in schizophrenia
Möller, T. J., Georgie, Y. K., Schillaci, G., Voss, M., Hafner, V. V., & Kaltwasser, L. (2021) · Consciousness and Cognition · doi:10.1016/j.concog.2021.103155 · Cited by 18 · see citing works
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 18 · see citing works
Armstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 17 · see citing works
Mallaroni, P., Mason, N. L., Vinckenbosch, F. R. J., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06142-4 · Cited by 16 · see citing works
Self-citationVeeraiah, P., & Jansen, J. F. A. (2023) · Metabolites · doi:10.3390/metabo13040577 · Cited by 16 · see citing works
Self-citation
- Authors
- Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., & Ramaekers, J. G.
- Affiliations
- Maastricht University (NL)
- University of Basel (CH)
- Goethe University Frankfurt (DE)
- Maastricht University Medical Centre (NL)
- Beckley Foundation (GB)
- Corresponding author
- Mason, N. L.
- Ramaekers, J. G.
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2020-05-23
- Volume
- 45
- Issue
- 12
- Pages
- 2003-2011
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC7547711
- OpenAlex
- W3027590463
- Cited by
- 258
- References
- 102
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 40 · 2023: 62 · 2022: 42 · 2021: 32 · 2020: 5
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Beckley Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psilocybin, glutamate, ego dissolution, self-experience, medial prefrontal cortex, hippocampus, subjective experience, psychedelics, depression, ultra-high field MRI
- MeSH terms
- Ego, Hallucinogens, Humans, Psilocybin, Solubility, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review